Omeros Sells Exclusive Global Rights for Drug Zaltenibart to Novo Nordisk

Omeros Corporation (NASDAQ:OMER) is one of the Reddit stocks that will go to the moon. On October 15, Omeros Corporation and Novo Nordisk (NYSE:NVO) announced a definitive asset purchase and license agreement for the clinical-stage candidate drug zaltenibart (formerly OMS906). Under the agreement, Novo Nordisk will be granted exclusive global rights to develop and commercialize zaltenibart for all indications, which are focused on rare blood and kidney disorders.

The transaction is expected to close in Q4 2025. Zaltenibart is an investigational humanized monoclonal antibody designed to inhibit MASP-3 (mannan-binding lectin-associated serine protease-3), which acts as the key and most upstream activator of the alternative pathway of the complement system. Dysregulation of this system, a critical part of the immune system, is involved in the pathophysiology of a number of rare diseases.

Omeros Sells Exclusive Global Rights for Drug Zaltenibart to Novo Nordisk

Omeros has reported positive Phase 2 data for zaltenibart in paroxysmal nocturnal hemoglobinuri/PNH, which is a rare, acquired blood disorder. The compound has been well tolerated across clinical trials and is seen by Novo Nordisk as having a novel mode of action that could provide several advantages and potentially become a best-in-class treatment approach for various complement-mediated diseases, including PNH, and renal diseases like immunoglobulin A nephropathy/IgAN, C3 glomerulopathy, and atypical hemolytic uremic syndrome.

Omeros Corporation (NASDAQ:OMER) is a clinical-stage biopharmaceutical company that discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases.

Novo Nordisk (NYSE:NVO), together with its subsidiaries, researches & develops, manufactures, and distributes pharmaceutical products internationally. It operates in two segments: Diabetes and Obesity Care and Rare Disease.

While we acknowledge the potential of OMER to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than OMER and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.